A 58-year-old man with established type 2 diabetes mellitus for 10 years, previous myocardial infarction, and an HbA1c of 8.2% is taking maximally tolerated metformin. His eGFR is 70 mL/min/1.73 m². According to Diabetes Canada pharmacologic management guidance, which additional agent is preferred to reduce cardiovascular risk?